CA2542509A1 - Salts of pharmacologically active compounds - Google Patents

Salts of pharmacologically active compounds Download PDF

Info

Publication number
CA2542509A1
CA2542509A1 CA002542509A CA2542509A CA2542509A1 CA 2542509 A1 CA2542509 A1 CA 2542509A1 CA 002542509 A CA002542509 A CA 002542509A CA 2542509 A CA2542509 A CA 2542509A CA 2542509 A1 CA2542509 A1 CA 2542509A1
Authority
CA
Canada
Prior art keywords
pharmacologically active
proton
active ingredient
composition
flunixin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002542509A
Other languages
English (en)
French (fr)
Inventor
Yerramilli V. S. N. Murthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2542509A1 publication Critical patent/CA2542509A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002542509A 2003-10-29 2004-10-28 Salts of pharmacologically active compounds Abandoned CA2542509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51596703P 2003-10-29 2003-10-29
US60/515,967 2003-10-29
PCT/US2004/035540 WO2005044254A1 (en) 2003-10-29 2004-10-28 Salts of pharmacologically active compounds

Publications (1)

Publication Number Publication Date
CA2542509A1 true CA2542509A1 (en) 2005-05-19

Family

ID=34572865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002542509A Abandoned CA2542509A1 (en) 2003-10-29 2004-10-28 Salts of pharmacologically active compounds

Country Status (6)

Country Link
US (1) US20050148519A1 (https=)
EP (1) EP1677781A4 (https=)
JP (1) JP2007509949A (https=)
AU (1) AU2004287439A1 (https=)
CA (1) CA2542509A1 (https=)
WO (1) WO2005044254A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
NZ588686A (en) * 2011-01-20 2013-07-26 Bayer New Zealand Ltd Injectable composition comprising an NSAID and an antibiotic in a non-aqueous solvent for treating a microbial infection in a mammary gland
CN103957888B (zh) * 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
JP6777734B2 (ja) 2015-06-10 2020-10-28 ピードモント アニマル ヘルス インコーポレイテッド 注射可能な抗生物質製剤及びその使用
RU2666607C1 (ru) * 2017-05-03 2018-09-11 Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" Способ повышения стабильности инъекционной фармацевтической композиции
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US6479473B1 (en) * 1997-05-06 2002-11-12 Norbrook Laboratories Ltd. Long-acting antimicrobials
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
AU2003227517A1 (en) * 2002-05-23 2003-12-12 Danmarks Farmaceutiske Universitet Pharmacologically active salts
DE10227938B4 (de) * 2002-06-21 2006-07-20 Heraeus Kulzer Gmbh Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas

Also Published As

Publication number Publication date
EP1677781A4 (en) 2008-11-19
AU2004287439A1 (en) 2005-05-19
WO2005044254A1 (en) 2005-05-19
US20050148519A1 (en) 2005-07-07
EP1677781A1 (en) 2006-07-12
JP2007509949A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
JP4850390B2 (ja) 薬理学的に活性な化合物の制御送達のための注射用組成物
EP1313510B1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
AU2002335077A1 (en) Injectable compositions for the controlled delivery of pharmacologically active compound
Utz et al. Amphotericin B toxicity: combined clinical staff conference at the National Institutes of Health
KR20080016689A (ko) 약물주사가 가능한 새로운 형태의 조성물 및 이러한조성물을 위한 조제방법
US6946137B2 (en) Methods for the controlled delivery of pharmacologically active compounds
US20050049210A1 (en) Methods for the controlled delivery of pharmacologically active compounds
US20050148519A1 (en) Salts of pharmacologically active compounds
US7282487B2 (en) Method for treating bacterial infections in horses or pigs with tilmicosin
Butler Changes in renal function
BENNETT Review of selected aspects of pharmacology
UTZ General side effects
HILL Changes in renal morphology
CN1466458A (zh) 精氨酸在制备用于预防和治疗与静脉内施用药物相关的副作用的药物中的用途
BRANDRISS Anemia
HK1142831A (en) Injectable compositions for the controlled delivery of pharmacologically active compound
HK1142831B (en) Injectable compositions for the controlled delivery of pharmacologically active compound

Legal Events

Date Code Title Description
FZDE Discontinued